Leonard H Wexler
Overview
Explore the profile of Leonard H Wexler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
5176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jain U, Mathew A, Jain B, Feliciano E, Dee E, Wexler L, et al.
JAMA Pediatr
. 2024 Sep;
178(11):1221-1223.
PMID: 39312252
No abstract available.
2.
Sharma A, Dermawan J, Chiang S, Wexler L, Antonescu C
Am J Surg Pathol
. 2024 Aug;
PMID: 39210566
Embryonal rhabdomyosarcoma (ERMS) is the most common subtype of RMS, occurring in soft tissue and visceral sites of young children, and is associated with favorable outcomes. A subset occurs in...
3.
Saoud C, Dermawan J, Sharma A, Tap W, Wexler L, Antonescu C
Genes Chromosomes Cancer
. 2024 May;
63(5):e23238.
PMID: 38722224
Pleomorphic rhabdomyosarcoma (PRMS) is a rare and highly aggressive sarcoma, occurring mostly in the deep soft tissues of middle-aged adults and showing a variable degree of skeletal muscle differentiation. The...
4.
de Traux de Wardin H, Dermawan J, Vanoli F, Jiang S, Singer S, Chi P, et al.
JCO Precis Oncol
. 2024 Apr;
8:e2300597.
PMID: 38603649
Purpose: Alterations of the tumor suppressor gene is the second most frequent genetic event in embryonal rhabdomyosarcoma (ERMS), but its associations with clinicopathologic features, outcome, or coexisting molecular events are...
5.
Kinnaman M, Zaccaria S, Makohon-Moore A, Arnold B, Levine M, Gundem G, et al.
Cancer Res
. 2023 Oct;
83(22):3796-3812.
PMID: 37812025
Significance: The chemoresistant population in recurrent osteosarcoma is subclonal at diagnosis, emerges at the time of primary resection due to selective pressure from neoadjuvant chemotherapy, and is characterized by unique...
6.
de Traux de Wardin H, Dermawan J, Merlin M, Wexler L, Orbach D, Vanoli F, et al.
NPJ Precis Oncol
. 2023 Sep;
7(1):96.
PMID: 37730754
The genomic spectrum of rhabdomyosarcoma (RMS) progression from primary to relapse is not fully understood. In this pilot study, we explore the sensitivity of various targeted and whole-genome NGS platforms...
7.
de Traux de Wardin H, Xu B, Dermawan J, Smith M, Wolden S, Antonescu C, et al.
JCO Precis Oncol
. 2023 Jun;
7:e2200705.
PMID: 37315267
Purpose: Extremity rhabdomyosarcoma (RMS) is associated with a very poor outcome compared with other sites, mainly because of its high incidence of alveolar histology and regional lymph node involvement. To...
8.
Anderson P, Ghisoli M, Crompton B, Klega K, Wexler L, Slotkin E, et al.
Clin Cancer Res
. 2023 Feb;
29(9):1689-1697.
PMID: 36780200
Purpose: Treatment options for recurrent or refractory Ewing's sarcoma (ES) are limited. Vigil is a novel autologous tumor cell therapy expressing bi-shRNA furin/GMCSF plasmid, which previously demonstrated monotherapy activity in...
9.
Kinnaman M, Zaccaria S, Makohon-Moore A, Arnold B, Levine M, Gundem G, et al.
bioRxiv
. 2023 Jan;
PMID: 36711976
Multiple large-scale tumor genomic profiling efforts have been undertaken in osteosarcoma, however, little is known about the spatial and temporal intratumor heterogeneity and how it may drive treatment resistance. We...
10.
Ho D, Agaram N, Jean M, Suser S, Chu C, Vanderbilt C, et al.
Am J Pathol
. 2022 Dec;
193(3):341-349.
PMID: 36563747
Osteosarcoma is the most common primary bone cancer, whose standard treatment includes pre-operative chemotherapy followed by resection. Chemotherapy response is used for prognosis and management of patients. Necrosis is routinely...